Your browser doesn't support javascript.
Potential Antiviral Options against SARS-CoV-2 Infection.
Ianevski, Aleksandr; Yao, Rouan; Fenstad, Mona Høysæter; Biza, Svetlana; Zusinaite, Eva; Reisberg, Tuuli; Lysvand, Hilde; Løseth, Kirsti; Landsem, Veslemøy Malm; Malmring, Janne Fossum; Oksenych, Valentyn; Erlandsen, Sten Even; Aas, Per Arne; Hagen, Lars; Pettersen, Caroline H; Tenson, Tanel; Afset, Jan Egil; Nordbø, Svein Arne; Bjørås, Magnar; Kainov, Denis E.
  • Ianevski A; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
  • Yao R; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
  • Fenstad MH; Department of Medical Microbiology, St. Olavs Hospital, 7006 Trondheim, Norway.
  • Biza S; Department of Immunology and Transfusion Medicine, St. Olavs Hospital, 7006 Trondheim, Norway.
  • Zusinaite E; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
  • Reisberg T; Institute of Technology, University of Tartu, 50090 Tartu, Estonia.
  • Lysvand H; Institute of Genomics Core Facility, University of Tartu, 51010 Tartu, Estonia.
  • Løseth K; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
  • Landsem VM; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
  • Malmring JF; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
  • Oksenych V; Department of Medical Microbiology, St. Olavs Hospital, 7006 Trondheim, Norway.
  • Erlandsen SE; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
  • Aas PA; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
  • Hagen L; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
  • Pettersen CH; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
  • Tenson T; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
  • Afset JE; Institute of Technology, University of Tartu, 50090 Tartu, Estonia.
  • Nordbø SA; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
  • Bjørås M; Department of Medical Microbiology, St. Olavs Hospital, 7006 Trondheim, Norway.
  • Kainov DE; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7028 Trondheim, Norway.
Viruses ; 12(6)2020 06 13.
Article in English | MEDLINE | ID: covidwho-602214
ABSTRACT
As of June 2020, the number of people infected with severe acute respiratory coronavirus 2 (SARS-CoV-2) continues to skyrocket, with more than 6.7 million cases worldwide. Both the World Health Organization (WHO) and United Nations (UN) has highlighted the need for better control of SARS-CoV-2 infections. However, developing novel virus-specific vaccines, monoclonal antibodies and antiviral drugs against SARS-CoV-2 can be time-consuming and costly. Convalescent sera and safe-in-man broad-spectrum antivirals (BSAAs) are readily available treatment options. Here, we developed a neutralization assay using SARS-CoV-2 strain and Vero-E6 cells. We identified the most potent sera from recovered patients for the treatment of SARS-CoV-2-infected patients. We also screened 136 safe-in-man broad-spectrum antivirals against the SARS-CoV-2 infection in Vero-E6 cells and identified nelfinavir, salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine. We found that a combination of orally available virus-directed nelfinavir and host-directed amodiaquine exhibited the highest synergy. Finally, we developed a website to disseminate the knowledge on available and emerging treatments of COVID-19.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Neutralization Tests / Coronavirus Infections / Betacoronavirus Type of study: Observational study Topics: Vaccines Limits: Animals / Humans Language: English Year: 2020 Document Type: Article Affiliation country: V12060642

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Neutralization Tests / Coronavirus Infections / Betacoronavirus Type of study: Observational study Topics: Vaccines Limits: Animals / Humans Language: English Year: 2020 Document Type: Article Affiliation country: V12060642